Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Diabetic Macular Edema (DME) Market Size Changed, over the years?
The steady expansion of the diabetic macular edema (DME) market has been evident in recent times. The forecast shows an anticipated growth from $4.67 billion in 2024 to $4.89 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%. Factors such as the escalating incidence of diabetes, the rise in disorders related to edema, an increase in diabetic eye diseases, an aging population, and a surge in reported cases of blindness have all been instrumental in the growth observed during the historic period.
How Much Will the Diabetic Macular Edema (DME) Market Be Worth in 2029?
The market for Diabetic Macular Edema (DME) is projected to experience sustained growth in the coming years, with projections setting it at $5.82 billion by 2029, boasting a compound annual growth rate (CAGR) of 4.4%. The anticipated growth within this projection period can be correlated to factors such as enhanced access to healthcare services, escalated government spending on healthcare, heightened awareness concerning diabetic complications, increased reliance on telemedicine for ocular care, and the proliferation of dedicated diabetic eye care centers. Prominent trends foreseen in this prediction interval encompass the evolution of anti-VEGF treatments, the integration of corticosteroid implants, advancements in drug delivery frameworks, technological progression in retinal laser procedures, the implementation of AI-enabled diagnostic devices, and the embracement of minimally invasive surgical methodologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21169&type=smp
Which is the Largest Company in the Diabetic Macular Edema (DME) Market?
Major companies operating in the diabetic macular edema (DME) market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Carl Zeiss AG, Topcon Corporation, Ypsomed AG, ARKRAY Inc, Hugel Inc., Optos plc, Noven Pharmaceuticals Inc., Alimera Sciences Inc., Allergan plc.
What Are the Main Market Drivers in the Diabetic Macular Edema (DME) Industry?
The diabetic macular edema (DME) market is predicted to surge, driven by the growing incidence of diabetes. This rise can be linked to inactive behaviors, poor eating patterns, escalating rates of obesity, aging society, and hereditary factors. Diabetes leads to diabetic macular edema by impacting the retinal blood vessels, causing fluid leakage into the macula which in turn results in edema. A report generated by the Institute for Health Metrics and Evaluation, a US-based public health research center, stated in June 2023 that over half a billion people globally were dealing with diabetes. This figure is anticipated to more than double by accommodating 1.3 billion people by 2050. As a result, the expanding occurrence of diabetes is propelling the growth of the DME market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21169&type=smp
How Is the Diabetic Macular Edema (DME) Market Segments Structured?
The diabetic macular edema (DME) market covered in this report is segmented –
1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention
2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage
3) By Patient Demographics: Adults, Elderly, Children
4) By Route Of Administration: Intravitreal Injection, Topical, Systemic
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies
2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids
3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Surgical Intervention: Vitrectomy, Membrane Peeling
What Strategic Trends Are Transforming the Diabetic Macular Edema (DME) Market?
Leading companies in the diabetic macular edema (DME) treatment market are concentrating on technological enhancements, particularly in advanced drug therapies, to boost patient management and treatment results. Such therapies, considered as state-of-the-art treatments, apply new research and technology to enhance the treatment of complex health issues. They seek to increase efficacy, minimize side effects, and provide improved patient outcomes. For example, Novartis AG, a pharmaceutical firm based in Switzerland, proclaimed in March 2022 that the European Commission approved Beovu to treat visual impairment caused by DME. The approval resonated with the outcomes of the Phase III KESTREL and KITE studies, which evidenced Beovu’s effectiveness, comparable to aflibercept, in improving vision within one year. Remarkably, more than half of the patients treated with Beovu retained a 12-week treatment regimen, encountering fewer episodes of retinal fluid compared to those treated with aflibercept.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report
Which Global Regions Offer the Highest Growth in the Diabetic Macular Edema (DME) Market?
North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (DME) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21169
This Report Delivers Insight On:
1. How big is the diabetic macular edema (dme) market, and how is it changing globally?
2. Who are the major companies in the diabetic macular edema (dme) market, and how are they performing?
3. What are the key opportunities and risks in the diabetic macular edema (dme) market right now?
4. Which products or customer segments are growing the most in the diabetic macular edema (dme) market?
5. What factors are helping or slowing down the growth of the diabetic macular edema (dme) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model